Marie Johnson, CEO and founder of AUM Cardiovascular, lost her husband, Rob, to a heart attack. The tragedy led her to develop CADence, a handheld device that she believes will save lives by identifying telltale signs of cardiovascular disease.

George Wallace says his Intersect incubator created 13 companies over 20 years, and exited eight of them. That’s a pretty good batting average. But innovators like Wallace continue to innovate, not only with technology but also with finding new ways to create meaningful Medtech companies.

Baxter CEO Joe Almeida discusses the challenges of taking over the hospital-products maker, reshaping its culture, focusing its strategy for the future, and investing in its people.

Justin Barad talks about taking VR out of the gaming space with innovative software that will transform how orthopedic surgeons train in the OR.

Ask Endeavour Vision’s Katie Ellias what song best represents her career path to venture capital and she’d probably say, “The Long and Winding Road.” Hear how the VC established a career path that took her from Pre-Med plans to Medtronic and then Venture Capital.

Jonathan Norris of Silicon Valley Bank follows up his recent Medtech Conference presentation with insights on healthcare exits, the latest M&A chatter, the resurgence of biopharma deals, which type of Medtech start-up gets the most action, and the drastic decline in Series A device deals.

SightLine general partner Joe Biller shares his insights on the venture market, including advice for companies looking for – and working with – venture capital investors.

What steps did Boston Scientific – under Mahoney’s leadership – take to unlock such significant growth? In an interview at the Medtech Conference, Mahoney – interviewed by Kevin Hykes, CEO of Metavention - laid out some of the meaningful changes Boston Scientific made.

Serial entrepreneur Mike Berman shares how he’s seen the Medtech innovation sector evolve over the years. Times are tougher, but Berman sees reason for hope as well as concern.

This week, New Enterprise Associates – known to its friends as NEA – announced closing on a $3.3 billion venture capital fund, with roughly 10% of that total going to Medtech companies. We asked partner Justin Klein, MD, how might the $300 million or so invest in Medtech companies be deployed differently than in the prior fund.